• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

关于细菌金属蛋白酶在 COVID-19 相关细胞因子风暴中的作用。

On the role of bacterial metalloproteases in COVID-19 associated cytokine storm.

机构信息

Department of Morphology and Physiology, Faculty of Health Sciences, Semmelweis University, 17. Vas str., Budapest, 1088, Hungary.

I. Department of Internal Medicine and Gastroenterology, Department of Orthopaedics - COVID Quarantine, ÉKC New Saint John's Hospital, 1-3. Diós árok, Budapest, 1125, Hungary.

出版信息

Cell Commun Signal. 2021 Jan 13;19(1):7. doi: 10.1186/s12964-020-00699-3.

DOI:10.1186/s12964-020-00699-3
PMID:33441142
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7805260/
Abstract

The cytokine release syndrome or cytokine storm, which is the hyper-induction of inflammatory responses has a central role in the mortality rate of COVID-19 and some other viral infections. Interleukin-6 (IL-6) is a key player in the development of cytokine storms. Shedding of interleukin-6 receptor (IL-6Rα) results in the accumulation of soluble interleukin-6 receptors (sIL-6R). Only relatively few cells express membrane-bound IL-6Rα. However, sIL-6R can act on potentially all cells and organs through the ubiquitously expressed gp130, the coreceptor of IL-6Rα. Through this, so-called trans-signaling, IL-6-sIL-6R is a powerful factor in the development of cytokine storms and multiorgan involvement. Some bacteria (e.g., Serratia marcescens, Staphylococcus aureus, Pseudomonas aeruginosa, Listeria monocytogenes), commonly considered to cause co-infections during viral pneumonia, can directly induce the shedding of membrane receptors, including IL-6Rα, or enhance endogenous shedding mechanisms causing the increase of sIL-6R level. Here we hypothesise that bacteria promoting shedding and increase the sIL-6R level can be an important contributing factor for the development of cytokine storms. Therefore, inhibition of IL-6Rα shedding by drastically reducing the number of relevant bacteria may be a critical element in reducing the chance of a cytokine storm. Validation of this hypothesis can support the consideration of the prophylactic use of antibiotics more widely and at an earlier stage of infection to decrease the mortality rate of COVID-19. Video abstract.

摘要

细胞因子释放综合征或细胞因子风暴,即炎症反应的过度诱导,在 COVID-19 和一些其他病毒感染的死亡率中起着核心作用。白细胞介素 6(IL-6)是细胞因子风暴发展的关键因素。白细胞介素 6 受体(IL-6Rα)的脱落导致可溶性白细胞介素 6 受体(sIL-6R)的积累。只有相对较少的细胞表达膜结合的 IL-6Rα。然而,sIL-6R 可以通过普遍表达的 gp130(IL-6Rα 的核心受体)作用于潜在的所有细胞和器官。通过这种所谓的转信号,IL-6-sIL-6R 是细胞因子风暴和多器官受累发展的有力因素。一些细菌(例如粘质沙雷氏菌、金黄色葡萄球菌、铜绿假单胞菌、李斯特菌单核细胞增生症),通常被认为在病毒性肺炎期间会引起合并感染,可直接诱导膜受体(包括 IL-6Rα)脱落,或增强内源性脱落机制导致 sIL-6R 水平升高。在这里,我们假设促进脱落和增加 sIL-6R 水平的细菌可能是细胞因子风暴发展的一个重要因素。因此,通过大大减少相关细菌的数量来抑制 IL-6Rα 的脱落可能是降低细胞因子风暴机会的关键因素。验证这一假设可以支持更广泛地考虑预防性使用抗生素,并在感染的早期阶段使用抗生素,以降低 COVID-19 的死亡率。视频摘要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3281/7807448/197f59f1cf10/12964_2020_699_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3281/7807448/197f59f1cf10/12964_2020_699_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3281/7807448/197f59f1cf10/12964_2020_699_Fig1_HTML.jpg

相似文献

1
On the role of bacterial metalloproteases in COVID-19 associated cytokine storm.关于细菌金属蛋白酶在 COVID-19 相关细胞因子风暴中的作用。
Cell Commun Signal. 2021 Jan 13;19(1):7. doi: 10.1186/s12964-020-00699-3.
2
Soluble interleukin-6 receptor in the COVID-19 cytokine storm syndrome.可溶性白细胞介素-6 受体在 COVID-19 细胞因子风暴综合征中的作用。
Cell Rep Med. 2021 May 18;2(5):100269. doi: 10.1016/j.xcrm.2021.100269. Epub 2021 Apr 19.
3
Soluble interleukin-6 receptor (sIL-6R) makes IL-6R negative T cell line respond to IL-6; it inhibits TNF production.可溶性白细胞介素-6受体(sIL-6R)使白细胞介素-6受体阴性的T细胞系对白细胞介素-6产生反应;它抑制肿瘤坏死因子的产生。
Immunol Lett. 2000 Mar 1;71(3):143-8. doi: 10.1016/s0165-2478(00)00157-7.
4
IL-6 controls the innate immune response against Listeria monocytogenes via classical IL-6 signaling.IL-6 通过经典的 IL-6 信号通路控制机体对李斯特菌的固有免疫反应。
J Immunol. 2013 Jan 15;190(2):703-11. doi: 10.4049/jimmunol.1201044. Epub 2012 Dec 12.
5
The regenerative activity of interleukin-6.白细胞介素-6的再生活性。
Methods Mol Biol. 2013;982:59-77. doi: 10.1007/978-1-62703-308-4_4.
6
Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.托珠单抗:COVID-19 中细胞因子风暴综合征治疗的一种治疗选择。
Arch Med Res. 2020 Aug;51(6):595-597. doi: 10.1016/j.arcmed.2020.05.009. Epub 2020 May 21.
7
Shedding of the interleukin-6 (IL-6) receptor (gp80) determines the ability of IL-6 to induce gp130 phosphorylation in human osteoblasts.白细胞介素-6(IL-6)受体(gp80)的脱落决定了IL-6诱导人成骨细胞中gp130磷酸化的能力。
J Biol Chem. 2002 May 10;277(19):16879-87. doi: 10.1074/jbc.M200546200. Epub 2002 Mar 7.
8
The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling.白细胞介素 (IL)-6、IL-6·可溶性 IL-6 受体 (sIL-6R) 和 IL-6·sIL-6R·sgp130 复合物的平衡允许经典信号和转导信号同时发生。
J Biol Chem. 2018 May 4;293(18):6762-6775. doi: 10.1074/jbc.RA117.001163. Epub 2018 Mar 20.
9
A Hybrid Soluble gp130/Spike-Nanobody Fusion Protein Simultaneously Blocks Interleukin-6 -Signaling and Cellular Infection with SARS-CoV-2.一种可溶性 gp130/Spike-Nanobody 融合蛋白同时阻断白细胞介素 6 信号和 SARS-CoV-2 细胞感染。
J Virol. 2022 Feb 23;96(4):e0162221. doi: 10.1128/JVI.01622-21. Epub 2021 Dec 22.
10
ADAM17 controls IL-6 signaling by cleavage of the murine IL-6Rα from the cell surface of leukocytes during inflammatory responses.ADAM17通过在炎症反应期间从白细胞细胞表面切割小鼠IL-6Rα来控制IL-6信号传导。
J Leukoc Biol. 2016 May;99(5):749-60. doi: 10.1189/jlb.3A0515-207R. Epub 2015 Nov 11.

引用本文的文献

1
What do we know about IL-6 in COVID-19 so far?到目前为止,我们对新冠病毒中的白细胞介素-6了解多少?
Biophys Rep. 2021 Jun 30;7(3):193-206. doi: 10.52601/bpr.2021.200024.
2
Critical roles of cytokine storm and bacterial infection in patients with COVID-19: therapeutic potential of mesenchymal stem cells.细胞因子风暴和细菌感染在 COVID-19 患者中的关键作用:间充质干细胞的治疗潜力。
Inflammopharmacology. 2023 Feb;31(1):171-206. doi: 10.1007/s10787-022-01132-6. Epub 2023 Jan 4.
3
Amyloidogenesis: What Do We Know So Far?淀粉样变性:目前我们了解多少?

本文引用的文献

1
SARS-CoV-2 Causes a Different Cytokine Response Compared to Other Cytokine Storm-Causing Respiratory Viruses in Severely Ill Patients.SARS-CoV-2 引起的细胞因子反应与其他严重感染患者中导致细胞因子风暴的呼吸道病毒不同。
Front Immunol. 2021 Mar 1;12:629193. doi: 10.3389/fimmu.2021.629193. eCollection 2021.
2
Biomimetic Human Disease Model of SARS-CoV-2-Induced Lung Injury and Immune Responses on Organ Chip System.基于器官芯片系统的SARS-CoV-2诱导的肺损伤和免疫反应的仿生人类疾病模型
Adv Sci (Weinh). 2020 Dec 21;8(3):2002928. doi: 10.1002/advs.202002928. eCollection 2021 Feb.
3
Insights into disparities observed with COVID-19.
Int J Mol Sci. 2022 Nov 12;23(22):13970. doi: 10.3390/ijms232213970.
4
Evaluating the structural and immune mechanism of Interleukin-6 for the investigation of goat milk peptides as potential treatments for COVID-19.评估白细胞介素-6的结构和免疫机制,以研究山羊奶肽作为治疗COVID-19的潜在疗法。
J King Saud Univ Sci. 2022 Jun;34(4):101924. doi: 10.1016/j.jksus.2022.101924. Epub 2022 Feb 25.
对观察到的 COVID-19 差异的深入了解。
J Intern Med. 2021 Apr;289(4):463-473. doi: 10.1111/joim.13199. Epub 2020 Dec 6.
4
Animal models for COVID-19.用于 COVID-19 的动物模型。
Nature. 2020 Oct;586(7830):509-515. doi: 10.1038/s41586-020-2787-6. Epub 2020 Sep 23.
5
An inflammatory cytokine signature predicts COVID-19 severity and survival.炎症细胞因子特征可预测 COVID-19 严重程度和存活情况。
Nat Med. 2020 Oct;26(10):1636-1643. doi: 10.1038/s41591-020-1051-9. Epub 2020 Aug 24.
6
Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study.重症监护病房中新冠肺炎患者使用托珠单抗的多中心观察性研究。
Lancet Rheumatol. 2020 Oct;2(10):e603-e612. doi: 10.1016/S2665-9913(20)30277-0. Epub 2020 Aug 14.
7
Overview: Systemic Inflammatory Response Derived From Lung Injury Caused by SARS-CoV-2 Infection Explains Severe Outcomes in COVID-19.概述:由 SARS-CoV-2 感染引起的肺损伤导致的全身炎症反应解释了 COVID-19 的严重结局。
Front Immunol. 2020 Jun 26;11:1626. doi: 10.3389/fimmu.2020.01626. eCollection 2020.
8
Tocilizumab for severe COVID-19: a systematic review and meta-analysis.托珠单抗治疗重症 COVID-19:系统评价和荟萃分析。
Int J Antimicrob Agents. 2020 Sep;56(3):106103. doi: 10.1016/j.ijantimicag.2020.106103. Epub 2020 Jul 23.
9
Black-White Risk Differentials in COVID-19 (SARS-COV2) Transmission, Mortality and Case Fatality in the United States: Translational Epidemiologic Perspective and Challenges.美国 COVID-19(SARS-COV2)传播、死亡率和病死率的黑-白风险差异:转化流行病学视角和挑战。
Int J Environ Res Public Health. 2020 Jun 17;17(12):4322. doi: 10.3390/ijerph17124322.
10
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study.托珠单抗治疗重症 COVID-19 患者的疗效和安全性:一项单中心回顾性队列研究。
Eur J Intern Med. 2020 Jun;76:43-49. doi: 10.1016/j.ejim.2020.05.021. Epub 2020 May 22.